Custom Lucite, with an embedded champagne cork, celebrating the approval by the Food and Drug Administration (FDA) of the obesity treatment Plenity. Plenity was developed by Boston-based biotech firm Gelesis.
(9AMF149)
Custom Lucite, with an embedded champagne cork, celebrating the approval by the Food and Drug Administration (FDA) of the obesity treatment Plenity. Plenity was developed by Boston-based biotech firm Gelesis.
(9AMF149)Custom crystal celebrating the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA). The application, related to Impel NeuroPharma’s migraine treatment INP104, was supported by a Phase 3, open-label STOP-301 Trial.
(20ALJ356)Lucite embedment with drug vial commemorating a study of a treatment for solid tumor cancer.
(21ADH006)Custom crystal celebrating FDA acceptance of the Investigational Drug Application for XTX101, a potential treatment for cancer patients.
(21AJH115)Diamond-shaped crystal deal toy commemorating a follow-on stock offering by Swiss biotech firm Oculis. (23AKL262)
Lucite commemorative marking the first patient dosed in a clinical study involving LunAIRo. Developed by Apnimed, the drug is intended for the treatment of obstructive sleep apnea. (23AZH173)
